FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:1555-1557 November 19, 1998 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Decousus, H. Related Article by Goldhaber, S. Z.

To the Editor: In his article on pulmonary embolism, Dr. Goldhaber (July 9 issue)¹ states that unfractionated heparin "constitutes the cornerstone" of treatment, and he mentions fractionated, or low-molecular-weight, heparin only in the discussion of prevention. Nevertheless, there have been two randomized trials in patients with pulmonary embolism that show that low-molecular-weight heparin is as effective as unfractionated heparin in regard to the incidence of recurrence, major bleeding complications, and death. In one study, which involved 612 patients with symptomatic pulmonary embolism who did not require thrombolytic therapy or embolectomy, subcutaneous low-molecular-weight heparin (tinzaparin) given once daily in a fixed . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.